Evolution of HIV Epidemic and Emerging Challenges—China,1989–2023
作者机构:National Center for AIDS/STD Control and PreventionChinese Center for Disease Control and PreventionBeijingChina National Key Laboratory of Intelligent Tracking and Forecasting for Infectious DiseasesNational Center for AIDS/STD Control and PreventionChinese Center for Disease Control and PreventionBeijingChina
出 版 物:《China CDC weekly》 (中国疾病预防控制中心周报(英文))
年 卷 期:2024年第6卷第48期
页 面:1251-1256页
核心收录:
学科分类:1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
基 金:Supported by the National Key Research and Development Plan(Grant number 2022YFC2305201)
主 题:prevention elevated IDU
摘 要:Introduction:This study aimed to provide a comprehensive analysis of the human immunodeficiency virus(HIV)epidemiological landscape in China through a historical review and current ***:Data were extracted from China’s HIV/AIDS Comprehensive Response Information Management System(CRIMS).Transmission patterns across different phases were visualized using stacked area *** correlations between transmission routes were analyzed using scatter plots and Pearson correlation *** extent and trends of HIV spread among the general population were evaluated using Venn diagrams and Cochran-Armitage ***:The HIV epidemic in China evolved through four distinct phases:injecting drug user(IDU)dominated(1989–1994),former plasma donor(FPD)outbreak(1995–2005),sexual transmission dominance(2006–2014),and general population spread(2015–present).A strong correlation was observed between provinces reporting high numbers of IDU cases and those with elevated heterosexual transmission(r=0.88,P0.001).Between 2015 and 2023,393,926 cases were identified among the general population through non-marital and non-commercial heterosexual contact(NMNCHC).The proportion of general population cases among heterosexual transmissions increased significantly from 46.2%to 55.7%(Z=42.7,P0.001).Conclusion:The significant spread of HIV into the general population necessitates the development of targeted prevention strategies for both high-risk and general populations to address emerging epidemiological challenges.